Immunomodulatory therapies in neurologic critical care

Neurocritical Care

Volumn 12, Issue 1, 2010, Pages 132-143

  McDaneld, Logan M ^a   Fields, Jeremy D ^a   Bourdette, Dennis N ^a   Bhardwaj, Anish ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosteroids; Cyclophosphamide; Immunoglobulin; Immunomodulation; Plasmapheresis

Indexed keywords

ALBUMIN; ALEMTUZUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; CHOLINESTERASE INHIBITOR; CITRIC ACID; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DEXAMETHASONE; ETANERCEPT; FRESH FROZEN PLASMA; HEPARIN; IBUPROFEN; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NEUROMUSCULAR BLOCKING AGENT; PLASMA SUBSTITUTE; PREDNISONE; RITUXIMAB; SODIUM CHLORIDE;

ACUTE DEMYELINATING ENCEPHALOMYELITIS; AGITATION; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTERY THROMBOSIS; ARTHRALGIA; ASEPTIC MENINGITIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL MENINGITIS; BLEEDING; BRAIN DISEASE; CARDIOTOXICITY; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; COCHRANE LIBRARY; COLLOID; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DEMYELINATING DISEASE; DIGESTIVE SYSTEM ULCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; ENCEPHALITIS; EPILEPTIC STATE; GUILLAIN BARRE SYNDROME; HASHIMOTO ENCEPHALOPATHY; HEMOLYTIC UREMIC SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; IMMUNOMODULATION; INFECTION RISK; INTENSIVE CARE; KIDNEY FAILURE; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; MEDLINE; MULTIFOCAL MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; MYOPATHY; NEUROLOGIC DISEASE; NEUROPATHY; PARANEOPLASTIC ENCEPHALITIS; PLASMAPHERESIS; PRIMARY CENTRAL NERVOUS SYSTEM VASCULITIS; PRIORITY JOURNAL; PSYCHOSIS; PUBLICATION; RASMUSSEN SYNDROME; RECOMMENDED DRUG DOSE; REVIEW; RISK; SALIVATION; SIDE EFFECT; STEROID RESPONSIVE ENCEPHALOPATHY; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRACHEOBRONCHIAL SECRETION; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VIRUS ENCEPHALITIS; WEST SYNDROME;

ADRENAL CORTEX HORMONES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CRITICAL CARE; CRITICAL ILLNESS; CYCLOPHOSPHAMIDE; ENCEPHALITIS; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; EVIDENCE-BASED MEDICINE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRACTICE GUIDELINES AS TOPIC; STATUS EPILEPTICUS;

EID: 76649086675     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-009-9274-0     Document Type: Review

References (175)

1. G Broessner R Helbok P Lackner, et al. 2007 Survival and long-term functional outcome in 1,155 consecutive neurocritical care patients Crit Care Med 35 2025 2030 17855816
2. JA Gomes RD Stevens JJ Lewin III MA Mirski A Bhardwaj 2005 Glucocorticoid therapy in neurologic critical care Crit Care Med 33 1214 1224 15942333
3. BJ Parker IN Bruce 2007 High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus Lupus 16 387 393 17664228
4. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;001331.
5. C Lindberg O Andersen AK Lefvert 1998 Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study Acta Neurol Scand 97 370 373 9669469
6. HC Lehmann HP Hartung GR Hetzel O Stuve BC Kieseier 2006 Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders Arch Neurol 63 930 935 16831960
7. MH Mokrzycki AA Kaplan 1994 Therapeutic plasma exchange: complications and management Am J Kidney Dis 23 817 827 8203364
8. AJ Keller SJ Urbaniak 1978 Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components Br J Haematol 38 531 540 646951
9. JH Yeh HC Chiu 2000 Plasmapheresis-related hypotension Artif Organs 24 705 709 11012540
10. R Gold M Stangel MC Dalakas 2007 Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues Nat Clin Pract Neurol 3 36 44 17205073
11. SV Kaveri S Lacroix-Desmazes J Bayry 2008 The antiinflammatory IgG N Engl J Med 359 307 309 18635437
12. MD Kazatchkine SV Kaveri 2001 Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin N Engl J Med 345 747 755 11547745
13. D Paran Y Herishanu O Elkayam L Shopin R Ben-Ami 2005 Venous and arterial thrombosis following administration of intravenous immunoglobulins. [see comment] Blood Coagul Fibrinol 16 313 318 (Pubitemid 41008736)
14. M Ballow 2007 Safety of IGIV therapy and infusion-related adverse events Immunol Res 38 122 132 17917017
15. H Orbach U Katz Y Sherer Y Shoenfeld 2005 Intravenous immunoglobulin: adverse effects and safe administration Clin Rev Allergy Immunol 29 173 184 16391392 (Pubitemid 43041668)
16. AK Asbury DR Cornblath 1990 Assessment of current diagnostic criteria for Guillain-Barre syndrome [see comment] Ann Neurol 27 S21 S24 2194422
17. RA Hughes JH Rees 1997 Clinical and epidemiologic features of Guillain-Barre syndrome J Infect Dis 176 S92 S98 9396689
18. Bosch PE, Smith BE. Disorders of peripheral nerves. In: Neurology in clinical practice. 5th ed. Philadelphia: Butterworth-Heinemann; 2004. p. 2336-2345.
19. DW Zochodne 1994 Autonomic involvement in Guillain-Barre syndrome: a review Muscle Nerve 17 1145 1155 7935521
20. RA Bernsen AE de Jager PI Schmitz FG van der Meche 1999 Residual physical outcome and daily living 3 to 6 years after Guillain-Barre syndrome Neurology 53 409 410 10430437
21. PA van Doorn L Ruts BC Jacobs 2008 Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome [see comment] Lancet Neurol 7 939 950 18848313
22. HJ Willison N Yuki 2002 Peripheral neuropathies and anti-glycolipid antibodies Brain 125 2591 2625 12429589
23. D Chowdhury A Arora 2001 Axonal Guillain-Barre syndrome: a critical review Acta Neurol Scand 103 267 277 11328201
24. CE Hafer-Macko KA Sheikh CY Li, et al. 1996 Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy Ann Neurol 39 625 635 8619548
25. C Hafer-Macko ST Hsieh CY Li, et al. 1996 Acute motor axonal neuropathy: an antibody-mediated attack on axolemma Ann Neurol 40 635 644 8871584
26. The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology. 1985;35:1096-104.
27. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol. 1987;22:753-61.
28. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome [update of Cochrane Database Syst Rev. 2001;(2):CD001798; PMID: 11406009]. Cochrane Database Syst Rev. 2002;001798.
29. FG van der Meche PI Schmitz 1992 A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group N Engl J Med 326 1123 1129 1552913
30. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome [update of Cochrane Database Syst Rev. 2004;(1):CD002063; PMID: 14973982]. Cochrane Database Syst Rev. 2006;002063.
31. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349:225-30.
32. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barre syndrome [update of Cochrane Database Syst Rev. 2000;(3):CD001446; PMID: 10908498]. Cochrane Database Syst Rev. 2006;001446.
33. RA Hughes EF Wijdicks R Barohn, et al. 2003 Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 61 736 740 14504313
34. RJ Barohn JT Kissel JR Warmolts JR Mendell 1989 Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria Arch Neurol 46 878 884 2757528
35. PA McCombe JD Pollard JG McLeod 1987 Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases Brain 110 1617 1630 3427403
36. PJ Dyck PC O'Brien KF Oviatt, et al. 1982 Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment Ann Neurol 11 136 141 7041788
37. PJ Dyck J Daube P O'Brien, et al. 1986 Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy N Engl J Med 314 461 465 3511382
38. AF Hahn CF Bolton N Pillay, et al. 1996 Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study Brain 119 1055 1066 8813270
39. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev. 2002;(2):CD001797; PMID: 12076423]. Cochrane Database Syst Rev. 2009;001797.
40. PJ Dyck WJ Litchy KM Kratz, et al. 1994 A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy Ann Neurol 36 838 845 7998769
41. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev. 2003;(1):CD003280; PMID: 12535467]. Cochrane Database Syst Rev. 2004;003280.
42. JJ Kelly Jr RA Kyle PC O'Brien PJ Dyck 1981 Prevalence of monoclonal protein in peripheral neuropathy Neurology 31 1480 1483 6273767
43. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies [update of Cochrane Database Syst Rev. 2003;(1):CD002827; PMID: 12535440]. Cochrane Database Syst Rev. 2006;002827.
44. MC Dalakas G Rakocevic M Salajegheh, et al. 2009 Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy Ann Neurol 65 286 293 19334068
45. Allen D, Lunn MP, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev. 2007;005376.
46. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;004429.
47. Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy [update of Cochrane Database Syst Rev. 2005;(3):CD003217; PMID: 16034892]. Cochrane Database Syst Rev. 2009;003217.
48. Vrancken AF, Hughes RA, Said G, Wokke JH, Notermans NC. Immunosuppressive treatment for non-systemic vasculitic neuropathy. Cochrane Database Syst Rev. 2007;006050.
49. S Ahmed JF Kirmani N Janjua, et al. 2005 An update on myasthenic crisis Curr Treat Opt Neurol 7 129 141
50. D Grob N Brunner T Namba M Pagala 2008 Lifetime course of myasthenia gravis Muscle Nerve 37 141 149 18059039
51. JM Lindstrom 2000 Acetylcholine receptors and myasthenia Muscle Nerve 23 453 477 10716755
52. A Vincent J Palace D Hilton-Jones 2001 Myasthenia gravis Lancet 357 2122 2128 11445126
53. S Tzartos S Hochschwender P Vasquez J Lindstrom 1987 Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor J Neuroimmunol 15 185 194 3495549
54. J McConville ME Farrugia D Beeson, et al. 2004 Detection and characterization of MuSK antibodies in seronegative myasthenia gravis Ann Neurol 55 580 584 15048899
55. J Berrouschot I Baumann P Kalischewski M Sterker D Schneider 1997 Therapy of myasthenic crisis [see comment] Crit Care Med 25 1228 1235 9233752
56. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;002828.
57. MB Bromberg O Carter 2004 Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data Muscle Nerve 30 20 37 15221875
58. A Jani-Acsadi RP Lisak 2007 Myasthenic crisis: guidelines for prevention and treatment J Neurol Sci 261 127 133 17544450
59. C Antozzi M Gemma B Regi, et al. 1991 A short plasma exchange protocol is effective in severe myasthenia gravis J Neurol 238 103 107 1856735
60. JH Yeh HC Chiu 1999 Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule Acta Neurol Scand 99 147 151 10100957
61. R Weinstein 2000 Therapeutic apheresis in neurological disorders J Clin Apheresis 15 74 128 10767052
62. DP Richman MA Agius 2003 Treatment of autoimmune myasthenia gravis [see comment] Neurology 61 1652 1661 14694025
63. L Zinman E Ng V Bril 2007 IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial Neurology 68 837 841 17353471
64. P Gajdos S Chevret B Clair C Tranchant C Chastang 1997 Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group Ann Neurol 41 789 796 9189040
65. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis [update in Cochrane Database Syst Rev. 2008;(1):CD002277; PMID: 18254004][update of Cochrane Database Syst Rev. 2003;(2):CD002277; PMID: 12804431]. Cochrane Database Syst Rev. 2006;002277.
66. N Shibuya T Sato M Osame T Takegami S Doi S Kawanami 1994 Immunoadsorption therapy for myasthenia gravis J Neurol Neurosurg Psychiatry 57 578 581 8201327
67. HL Weiner JA Cohen 2002 Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Multiple Sclerosis 8 142 154 11990872
68. S Tenembaum T Chitnis J Ness JS Hahn International Pediatric MS Study G 2007 Acute disseminated encephalomyelitis Neurology 68 S23 S36 17438235
69. PS Sorensen SI Mellgren A Svenningsson, et al. 2009 NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial Lancet Neurol 8 519 529 19409854
70. S Schwarz A Mohr M Knauth B Wildemann B Storch-Hagenlocher 2001 Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients Neurology 56 1313 1318 11376180
71. PS Sorensen J Haas F Sellebjerg T Olsson M Ravnborg TARIMS Study G 2004 IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS Neurology 63 2028 2033 15596745
72. S Tenembaum N Chamoles N Fejerman 2002 Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients Neurology 59 1224 1231 12391351
73. P Jacquerye M Ossemann P Laloux A Dive B De Coene 1999 Acute fulminant multiple sclerosis and plasma exchange Eur Neurol 41 174 175 10202254
74. Y Mao-Draayer S Braff W Pendlebury H Panitch 2002 Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange Neurology 59 1074 1077 12370466
75. M Rodriguez WE Karnes JD Bartleson AA Pineda 1993 Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination Neurology 43 1100 1104 8170550
76. R RamachandranNair M Parameswaran AS Girija 2005 Acute disseminated encephalomyelitis treated with plasmapheresis Singapore Med J 46 561 563 16172778
77. DS Kanter D Horensky RA Sperling JD Kaplan ME Malachowski WH Churchill Jr 1995 Plasmapheresis in fulminant acute disseminated encephalomyelitis Neurology 45 824 827 7723979
78. LJ Ryan R Bowman ND Zantek, et al. 2007 Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature Transfusion 47 981 986 17524086
79. HL Weiner PC Dau BO Khatri, et al. 1989 Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis Neurology 39 1143 1149 2549450
80. BG Weinshenker PC O'Brien TM Petterson, et al. 1999 A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease Ann Neurol 46 878 886 10589540
81. M Keegan AA Pineda RL McClelland CH Darby M Rodriguez BG Weinshenker 2002 Plasma exchange for severe attacks of CNS demyelination: predictors of response Neurology 58 143 146 11781423
82. M Nishikawa T Ichiyama T Hayashi K Ouchi S Furukawa 1999 Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis Pediatr Neurol 21 583 586 10465150
83. M Kleiman P Brunquell 1995 Acute disseminated encephalomyelitis: response to intravenous immunoglobulin J Child Neurol 10 481 483 8576561
84. S Pradhan RP Gupta S Shashank N Pandey 1999 Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis J Neurol Sci 165 56 61 10426148
85. JS Hahn DJ Siegler D Enzmann 1996 Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis Neurology 46 1173 1174 8780119
86. DJ Sahlas SP Miller M Guerin M Veilleux G Francis 2000 Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin Neurology 54 1370 1372 10746613
87. J Finsterer R Grass C Stollberger B Mamoli 1998 Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis Clin Neuropharmacol 21 258 261 9704169
88. R Markus BJ Brew J Turner M Pell 1997 Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis J Neurol Neurosurg Psychiatry 63 551 9343149
89. E Marchioni K Marinou-Aktipi C Uggetti, et al. 2002 Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis J Neurol 249 100 104 11954856
90. DC Fu JR Montgomery 2008 High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis Neurology 71 294 295 18645168
91. RP Lu G Keilson 2006 Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis J Clin Apheresis 21 260 265 16868969
92. E Shahar J Andraus D Savitzki G Pilar N Zelnik 2002 Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins J Child Neurol 17 810 814 12585719
93. S Ravaglia G Piccolo M Ceroni, et al. 2007 Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg J Neurol 254 1518 1523 17965959
94. LH Visser R Beekman CC Tijssen, et al. 2004 A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS Multiple Sclerosis 10 89 91 14760960
95. Y Kanaheswari J Baizura M Paeds A Zulfiqar 2004 Intravenous immunoglobulin in the treatment of acute disseminated encephalomyelitis Med J Malaysia 59 103 107 15535344
96. V Kimiskidis I Sakellari V Tsimourtou, et al. 2008 Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome Multiple Sclerosis 14 278 283 17942513
97. HP Hartung R Gonsette N Konig H Kwiecinski A Guseo SP Morrissey H Krapf T Zwingers Mitoxantrone in Multiple Sclerosis Study Group (MIMS) 2002 Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2018 2025 12504397
98. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005;002127.
99. RE Gonsette 2003 Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206 203 208 12559512
100. A Boster G Edan E Frohman A Javed O Stuve A Tselis H Weiner B Weinstock-Guttman O Khan 2008 Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician Lancet Neurol 7 173 183 18207115
101. SL Hauser DM Dawson JR Lehrich, et al. 1983 Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH N Engl J Med 308 173 180 6294517
102. WH Likosky B Fireman R Elmore, et al. 1991 Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study Journal of Neurol Neurosurg Psychiatry 54 1055 1060
103. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337:441-6.
104. RE Gonsette L Demonty P Delmotte 1977 Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years J Neurol 214 173 181 65452
105. B Weinstock-Guttman RP Kinkel JA Cohen, et al. 1997 Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide Neurologist 3 178 185
106. OA Khan M Zvartau-Hind C Caon, et al. 2001 Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy Multiple Sclerosis 7 185 188 11475443
107. F Patti ML Cataldi F Nicoletti E Reggio A Nicoletti A Reggio 2001 Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis J Neurol Neurosurg Psychiatry 71 404 407 11511721
108. DE Gladstone KW Zamkoff L Krupp, et al. 2006 High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis Arch Neurol 63 1388 1393 16908728
109. Y Blanco A Saiz E Carreras F Graus 2005 Autologous haematopoietic-stem- cell transplantation for multiple sclerosis Lancet Neurol 4 54 63 15620857
110. A Fassas A Anagnostopoulos A Kazis, et al. 2000 Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy J Clin Immunol 20 24 30 10798604
111. A Fassas JR Passweg A Anagnostopoulos A Kazis T Kozak E Havrdova E Carreras F Graus A Kashyap H Openshaw M Schipperus E Deconinck G Mancardi A Marmont J Hansz M Rabusin FJ Zuazu Nagore J Besalduch T Dentamaro L Fouillard B Hertenstein G La Nasa M Musso F Papineschi JM Rowe R Saccardi A Steck L Kappos A Gratwohl A Tyndall J Samijn 2002 Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study J Neurol 249 1088 1097 12195460
112. A Saiz Y Blanco E Carreras, et al. 2004 Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS Neurology 62 282 284 14745069
113. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis [see comment] [update of Cochrane Database Syst Rev. 2003;(3):CD004405; PMID: 12918010]. Cochrane Database Syst Rev. 2007;004405.
114. M Ozen G Kanra A Kara, et al. 2006 Long-term beneficial effects of dexamethasone on intellectual and neuropsychological outcome of children with pneumococcal meningitis Scand J Infect Dis 38 104 109 16449000
115. M Scarborough SB Gordon CJ Whitty, et al. 2007 Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa N Engl J Med 357 2441 2450 18077809
116. AR Tunkel BJ Hartman SL Kaplan, et al. 2004 Practice guidelines for the management of bacterial meningitis Clin Infect Dis 39 1267 1284 15494903
117. TH Nguyen TH Tran G Thwaites, et al. 2007 Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis N Engl J Med 357 2431 2440 18077808
118. S Kamei T Sekizawa H Shiota, et al. 2005 Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis J Neurol Neurosurg Psychiatry 76 1544 1549 16227548
119. Martinez-Torres F, Menon S, Pritsch M, et al. Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. 2008;8:40.
120. C Salvarani RD Brown Jr KT Calamia, et al. 2007 Primary central nervous system vasculitis: analysis of 101 patients Ann Neurol 62 442 451 17924545
121. C Salvarani RD Brown Jr KT Calamia, et al. 2008 Primary central nervous system vasculitis with prominent leptomeningeal enhancement: a subset with a benign outcome Arthritis Rheumatism 58 595 603 18240248
122. C Salvarani RD Brown Jr KT Calamia, et al. 2008 Angiography-negative primary central nervous system vasculitis: a syndrome involving small cerebral vessels Medicine 87 264 271 18794709
123. S Lanthier A Lortie J Michaud R Laxer V Jay G deVeber 2001 Isolated angiitis of the CNS in children Neurology 56 837 842 11314698
124. SM Benseler E Silverman RI Aviv, et al. 2006 Primary central nervous system vasculitis in children Arthritis Rheumatism 54 1291 1297 16575852
125. LH Calabrese ES Molloy AB Singhal 2007 Primary central nervous system vasculitis: progress and questions Ann Neurol 62 430 432 18041087
126. TR Cupps PM Moore AS Fauci 1983 Isolated angiitis of the central nervous system. Prospective diagnostic and therapeutic experience Am J Med 74 97 105 6849332
127. PM Moore 1989 Diagnosis and management of isolated angiitis of the central nervous system Neurology 39 167 173 2915784
128. KJ Bitter LG Epstein H Melin-Aldana JG Curran ML Miller 2006 Cyclophosphamide treatment of primary angiitis of the central nervous system in children: report of 2 cases J Rheumatol 33 2078 2080 17014023
129. M Volcy ME Toro CS Uribe G Toro 2004 Primary angiitis of the central nervous system: report of five biopsy-confirmed cases from Colombia J Neurol Sci 227 85 89 15546596
130. A Siva 2001 Vasculitis of the nervous system J Neurol 248 451 468 11499635
131. RA Hajj-Ali S Ghamande LH Calabrese AC Arroliga 2002 Central nervous system vasculitis in the intensive care unit Crit Care Clin 18 897 914 12418446
132. PM Moore B Richardson 1998 Neurology of the vasculitides and connective tissue diseases J Neurol Neurosurg Psychiatry 65 10 22 9667555
133. C Salvarani RD Brown Jr KT Calamia, et al. 2008 Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment Arthritis Rheumatism 59 291 296 18240197
134. RB Darnell JB Posner 2003 Paraneoplastic syndromes involving the nervous system N Engl J Med 349 1543 1554 14561798
135. J Dalmau E Tuzun HY Wu, et al. 2007 Paraneoplastic anti-N-methyl-d- aspartate receptor encephalitis associated with ovarian teratoma Ann Neurol 61 25 36 17262855 (Pubitemid 46214241)
136. S Vernino BP O'Neill RS Marks JR O'Fallon DW Kimmel 2004 Immunomodulatory treatment trial for paraneoplastic neurological disorders Neuro-oncology 6 55 62 14769141
137. M Uchuya F Graus F Vega R Rene JY Delattre 1996 Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies J Neurol Neurosurg Psychiatry 60 388 392 8774401
138. F Graus F Vega JY Delattre, et al. 1992 Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies Neurology 42 536 540 1312683
139. NE Anderson MK Rosenblum F Graus RG Wiley JB Posner 1988 Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer Neurology 38 1391 1398 2842702
140. F Keime-Guibert F Graus A Fleury, et al. 2000 Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone J Neurol Neurosurg Psychiatry 68 479 482 10727484
141. YB David E Warner M Levitan DM Sutton MG Malkin JO Dalmau 1996 Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report Cancer 78 2153 2156 8918408
142. BM Ances R Vitaliani RA Taylor, et al. 2005 Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates Brain 128 1764 1777 15888538
143. J Dalmau AJ Gleichman EG Hughes, et al. 2008 Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies Lancet Neurol 7 1091 1098 18851928
144. A Vincent C Buckley JM Schott, et al. 2004 Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis Brain 127 701 712 14960497
145. P Pozo-Rosich L Clover A Saiz A Vincent F Graus 2003 Voltage-gated potassium channel antibodies in limbic encephalitis Ann Neurol 54 530 533 14520669
146. MJ Thieben VA Lennon BF Boeve AJ Aksamit M Keegan S Vernino 2004 Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody Neurology 62 1177 1182 15079019
147. C Buckley J Oger L Clover, et al. 2001 Potassium channel antibodies in two patients with reversible limbic encephalitis Ann Neurol 50 73 78 11456313
148. I Kothbauer-Margreiter M Sturzenegger J Komor R Baumgartner CW Hess 1996 Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment J Neurol 243 585 593 8865025
149. P Castillo B Woodruff R Caselli, et al. 2006 Steroid-responsive encephalopathy associated with autoimmune thyroiditis Arch Neurol 63 197 202 16476807
150. KA Josephs FA Rubino DW Dickson 2004 Nonvasculitic autoimmune inflammatory meningoencephalitis Neuropathology 24 149 152 15139593
151. JY Chong LP Rowland 2006 What's in a NAIM? Hashimoto encephalopathy, steroid-responsive encephalopathy associated with autoimmune thyroiditis, or nonvasculitic autoimmune meningoencephalitis?[comment] Arch Neurol 63 175 176 16476805
152. DJ Mahad S Staugaitis P Ruggieri, et al. 2005 Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination J Neurol Sci 228 3 5 15607202
153. E Ferlazzo M Raffaele I Mazzu F Pisani 2006 Recurrent status epilepticus as the main feature of Hashimoto's encephalopathy Epilepsy Behav 8 328 330 16343998
154. S Vernino M Geschwind B Boeve 2007 Autoimmune encephalopathies Neurologist 13 140 147 17495758
155. HC Chen U Marsharani 2000 Hashimoto's encephalopathy South Med J 93 504 506 10832952
156. RJ Caselli BF Boeve BW Scheithauer JD O'Duffy GG Hunder 1999 Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy Neurology 53 1579 1581 10534272
157. PJ Shaw TJ Walls PK Newman PG Cleland NE Cartlidge 1991 Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers-report of 5 cases Neurology 41 228 233 1992366
158. JY Chong LP Rowland RD Utiger 2003 Hashimoto encephalopathy: syndrome or myth? [see comment] Arch Neurol 60 164 171 12580699
159. R Mocellin M Walterfang D Velakoulis 2007 Hashimoto's encephalopathy: epidemiology, pathogenesis and management CNS Drugs 21 799 811 17850170
160. S Jacob YA Rajabally 2005 Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins J Neurol Neurosurg Psychiatry 76 455 456 15716552
161. E Wirkowski RB Libman M Batash 1998 Hashimot's encephalopathy-response to intravenous immunoglobulin J Stroke Cerebrovasc Dis 7 265 266 17895096
162. PM Boers JG Colebatch 2001 Hashimoto's encephalopathy responding to plasmapheresis J Neurol Neurosurg Psychiatry 70 132 11118266
163. NS Hussain J Rumbaugh D Kerr A Nath AE Hillis 2005 Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy Neurology 64 165 166 15642930
164. T Nagpal S Pande 2004 Hashimoto's encephalopathy: response to plasma exchange Neurol India 52 245 247 15269483
165. J Palace B Lang 2000 Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry 69 711 714 11080217
166. K McKnight Y Jiang Y Hart, et al. 2005 Serum antibodies in epilepsy and seizure-associated disorders Neurology 65 1730 1736 16344514
167. H Verhelst P Boon G Buyse, et al. 2005 Steroids in intractable childhood epilepsy: clinical experience and review of the literature Seizure 14 412 421 16087358 (Pubitemid 41200494)
168. DB Sinclair 2003 Prednisone therapy in pediatric epilepsy Pediatr Neurol 28 194 198 12770672
169. A Okumura T Tsuji T Kato J Natsume T Negoro K Watanabe 2006 ACTH therapy for generalized seizures other than spasms Seizure 15 469 475 16806994
170. AN Prasad CF Stafstrom GL Holmes 1996 Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids Epilepsia 37 S81 S95 8647056
171. CG Bien T Granata C Antozzi, et al. 2005 Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement Brain 128 454 471 15689357
172. PI Andrews MA Dichter SF Berkovic MR Newton JO McNamara 1996 Plasmapheresis in Rasmussen's encephalitis Neurology 46 242 246 8559385
173. M Lousa S Sanchez-Alonso R Rodriguez-Diaz J Dalmau 2000 Status epilepticus with neuron-reactive serum antibodies: response to plasma exchange Neurology 54 2163 2165 10851386
174. F Nahab A Heller SM Laroche 2008 Focal cortical resection for complex partial status epilepticus due to a paraneoplastic encephalitis Neurologist 14 56 59 18195661
175. L Mosca LJ Appel EJ Benjamin, et al. 2004 Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women Arterioscl Thromb Vasc Biol 24 394 396 15003972